| Cash Flow | 2025-09-30 |
|---|---|
| Consolidated net loss | -5,720 |
| Share-based compensation | 323 |
| Amortization of intangible assets | 5 |
| Amortization of finance lease right-of-use assets | 68 |
| Amortization of operating lease right-of-use assets | 93 |
| Depreciation of fixed assets | 123 |
| Accrued interest receivable on promissory note receivable | 19 |
| Amortization of premiums on debt securities | 9 |
| Accounts receivable - trade | 65 |
| Prepaid expenses and other current assets | 106 |
| Accounts payable | 495 |
| Accrued expenses | -686 |
| Operating lease obligations | -117 |
| Contract liabilities | -50 |
| Net cash used in operating activities | -5,665 |
| Purchases of debt securities | 21,461 |
| Purchase of fixed assets | 32 |
| Net cash (used in) provided by investing activities | -21,493 |
| Proceeds from sales of common stock | 219 |
| Proceeds from pre-funded warrants | 50,006 |
| Payments made for costs to acquire capital | 3,465 |
| Subscription receivable | 105 |
| Payment of equipment financing loan | 47 |
| Payment of term promissory note | 60 |
| Payment of finance lease obligation | 53 |
| Net cash provided by (used in) financing activities | 46,705 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 19,547 |
| Cash and cash equivalents at beginning of period | 8,792 |
| Cash and cash equivalents at end of period | 28,339 |
iBio, Inc. (IBIO)
iBio, Inc. (IBIO)